Abstract | AIM: MATERIAL AND METHODS: Antropometry, densitometry of fat tissue (FT) were made and parameters of fat and carbohydrate metabolism (lipidogram, glycated hemoglobin, immunoreactive insulin), FT secretory activity ( leptin, adiponectin, TNF-alpha) were studied in 75 obese DM-2 patients. After the above primary examination all the patients were randomized into 2 groups: group 1 (n = 55) received xenical (120 mg 3 times a day) and kept moderate hypocaloric diet; group 2 (n = 20) received only the above diet therapy. Active treatment lasted 24 weeks. RESULTS: CONCLUSION:
Xenical is beneficial for patients with DM-2 and obesity because it improves metabolic processes.
|
Authors | T Iu Demidova, A V Selivanova, A S Ametov |
Journal | Terapevticheskii arkhiv
(Ter Arkh)
Vol. 78
Issue 11
Pg. 64-9
( 2006)
ISSN: 0040-3660 [Print] Russia (Federation) |
PMID | 17195531
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Adiponectin
- Anti-Obesity Agents
- Biomarkers
- Glycated Hemoglobin A
- Insulin
- Lactones
- Leptin
- Lipids
- Tumor Necrosis Factor-alpha
- Orlistat
|
Topics |
- Adiponectin
(analysis, metabolism)
- Adipose Tissue
(anatomy & histology, metabolism)
- Anthropometry
- Anti-Obesity Agents
(pharmacology, therapeutic use)
- Biomarkers
(blood)
- Body Weight
(drug effects)
- Caloric Restriction
- Carbohydrate Metabolism
- Diabetes Mellitus, Type 2
(complications, diet therapy, drug therapy)
- Female
- Glycated Hemoglobin
(analysis)
- Humans
- Insulin
(blood, immunology)
- Insulin Resistance
- Lactones
(pharmacology, therapeutic use)
- Leptin
(analysis, metabolism)
- Lipids
(blood)
- Male
- Metabolic Syndrome
(diagnosis)
- Middle Aged
- Obesity
(complications, diet therapy, drug therapy)
- Orlistat
- Tumor Necrosis Factor-alpha
(analysis, metabolism)
|